AKTX

Akari Therapeutics Plc ADR (AKTX) | Rumor.io

Akari Therapeutics

AKTX

Attention (50-day avg)0%

Attention rank (50-day avg)#3,362

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization19.1M

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-17.3M

Social

What share of all stock conversation is about AKTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jul 7

Akari Therapeutics ($AKTX) has appointed Dr. Patricia LoRusso, a renowned oncology drug development leader, to its Scientific Advisory Board, which is a significant signal for the company's oncology development.
Dr. LoRusso has a strong track record in clinical trials, having run trials on 14 cancer drugs that later gained FDA approval, and has expertise in early-phase oncology trials and PARP inhibitor development.
The appointment of Dr. LoRusso has led to a significant increase in the stock price, with $AKTX rising 41% on the day of the announcement, and the stock is now up 39% from the previous day's close.

Generated by AI

Sentiment

Of the messages about AKTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	95.11% +27.59
Bearish	—	—	0% 0	4.89% -27.59

Bullish· May 29

Akari Therapeutics, Plc ($AKTX) has shown significant growth, gaining over 250% in a single session, indicating the market's reward for innovation and identifying asymmetric opportunities.
The company's cancer treatment has demonstrated better safety and efficacy compared to Trodelvy, acquired by Gilead Sciences for $21 billion, highlighting its potential for massive upside.
$AKTX is well-positioned to benefit from the growing demand for copper, which is becoming the infrastructure layer behind the entire AI economy, with a potential 50% growth projection by 2040.

Bearish· May 28

The borrow rate for $AKTX is extremely high at 982%, indicating potential liquidity issues.
The company's ADC technology may be less competitive due to Big Pharma's focus on acquiring ADC developers to replenish their pipelines.
Without a partnership, the recent price pump is considered "all noise" and may not be sustainable.

Generated by AI

Topics

Of the messages about AKTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	71.43%	58.63%
Technical Analysis	—	—	28.57%	23.45%
Analysts	—	—	0%	9.75%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	8.17%

Announcements· May 28

Akari Therapeutics' AKTX-101 demonstrated synergy with adagrasib in preclinical KRAS-driven pancreatic cancer models, highlighting the potential of the company's ADC platform.
The company's novel ADC platform uses RNA splicing modulator payloads, offering a differentiated angle in oncology.
CEO Abizer Gaslightwala discussed the breakthrough potential of AKTX-101 and the novel ADC platform in a virtual investor segment following ASCO abstract acceptance.

Technical Analysis· May 22

$AKTX is gearing up for another leg with potential to move to $15.73.
A bullish momentum is expected in the short term, with possible targets at $10+ for dip buys around $8-$9 and a push toward $20+ for breakout entries above $16.
The stock has shown strong momentum, with a 49.85% advance today on volume 44.6 times above average, and the RSI at 52.3 indicating a move with momentum without reaching overbought levels.

Generated by AI

Community

Of the messages about AKTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	85.71%	13.67%
Newcomers	—	—	14.29%	86.33%

Regulars· May 22

$AKTX, Akari Therapeutics, is a biotech developing antibody drug conjugates with a novel RNA splicing modulator payload for oncology, and its stock is up 90% premarket after announcing a $5.5M private placement financing round.
The company has released preclinical data for its lead ADC, AKTX-101, which showed potent single-agent activity and strong synergy with adagrasib in KRAS-mutant tumors, and has been highlighted as a breakthrough at the ASCO 2026 Annual Meeting.
$AKTX is forming a pennant and needs to break the VWAP at 10.43 to continue its upward momentum, with regulars closely watching its price action and technical analysis.

Newcomers· May 29

Akari Therapeutics, Plc ($AKTX) has gained over 250% in a single session, indicating the market's potential to reward innovation before revenue is realized.
The global copper supply is fragile due to structural mining issues, as evidenced by Chile's output decline, which may lead to supply constraints and higher prices.
$AKTX's setup has multiple catalysts, including copper macro trends, exploration at Wilmac, the MetalCore AI angle, and patent applications, making it a speculative yet potentially attractive opportunity.

Generated by AI

Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September CEO Abizer Gaslightwala to deliver keynote and featured presentations on next-generation ADC payload innovation and partnerships/collaborations TAMPA, Fla. and LONDON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing

22d agoYahoo Finance

Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference

Video webcast now available here TAMPA, Fla. and LONDON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that it participated in the Virtual Investor "Why Now" on-demand conference. During the webcast, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, presented the Company's investment thesis, highlighti

1mo agoYahoo Finance

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Moderna (MRNA) and Akari Therapeutics (AKTX)

Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy

1mo agoBenzinga

Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy

AKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models Data supports the potential of Akari’s novel PH1 RNA spliceosome-modulating payload to overcome payload-specific resistance Results strengthen the rationale for a differentiated ADC sequencing strategy as ADC use expands across oncology and more patients require treatment following relapse Akari advancing IND-enabling activities for AKTX-101 toward planned Phase 1 clinical de

1mo agoYahoo! Finance Canada

Akari Therapeutics targets mid-2027 phase 1 trial for AKTX-101

1mo agoInvesting.com

Also Discussed

Investors talking about AKTX also mention

#	Name	Attention
1	Bio-Path Holdings Inc.BPTH	0%0
2	Arcadia Biosciences Inc.RKDA	0.01%0
3	Pulmatrix Inc.PULM	0%0
4	Globus Maritime Limited Common StockGLBS	0%new
5	Moleculin Biotech, Inc.MBRX	0%0
6	AllianzIM U.S. Equity 6 Month Buffer10 Jun/Dec ETFSIXD	0%0
7	Omeros Corp.OMER	0%+0
8	NLTX - Neoleukin Therapeutics, Inc.	——
9	Invesco High Income Trust IIVLT	0%0
10	SLNO - Soleno Therapeutics, Inc.	——

Akari Therapeutics Plc ADR

Healthcare
Biotechnology

Akari Therapeutics Plc ADR is an oncology biotechnology company focused on developing antibody-drug conjugates designed to deliver cancer-killing payloads directly to tumor cells. The company’s current work centers on its ADC discovery platform, which combines targeted antibodies with novel RNA spliceosome-modulating payloads to create candidates aimed at solid tumors. Its lead program, AKTX-101, is a preclinical TROP2-targeted ADC being studied across multiple tumor types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, and prostate cancers. Akari Therapeutics also maintains a broader research focus on advanced therapies for autoimmune and inflammatory diseases. As an ADR issuer, Akari Therapeutics Plc provides investors access to its ordinary shares through a U.S.-traded depositary receipt structure while the company advances its biotechnology programs from its headquarters in Tampa, Florida.

Website

Location

401 East Jackson Street

Tampa, FL, 33602

United States

Social

What share of all stock conversation is about AKTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jul 7

Akari Therapeutics ($AKTX) has appointed Dr. Patricia LoRusso, a renowned oncology drug development leader, to its Scientific Advisory Board, which is a significant signal for the company's oncology development.
Dr. LoRusso has a strong track record in clinical trials, having run trials on 14 cancer drugs that later gained FDA approval, and has expertise in early-phase oncology trials and PARP inhibitor development.
The appointment of Dr. LoRusso has led to a significant increase in the stock price, with $AKTX rising 41% on the day of the announcement, and the stock is now up 39% from the previous day's close.

Generated by AI

Sentiment

Of the messages about AKTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	95.11% +27.59
Bearish	—	—	0% 0	4.89% -27.59

Bullish· May 29

Akari Therapeutics, Plc ($AKTX) has shown significant growth, gaining over 250% in a single session, indicating the market's reward for innovation and identifying asymmetric opportunities.
The company's cancer treatment has demonstrated better safety and efficacy compared to Trodelvy, acquired by Gilead Sciences for $21 billion, highlighting its potential for massive upside.
$AKTX is well-positioned to benefit from the growing demand for copper, which is becoming the infrastructure layer behind the entire AI economy, with a potential 50% growth projection by 2040.

Bearish· May 28

The borrow rate for $AKTX is extremely high at 982%, indicating potential liquidity issues.
The company's ADC technology may be less competitive due to Big Pharma's focus on acquiring ADC developers to replenish their pipelines.
Without a partnership, the recent price pump is considered "all noise" and may not be sustainable.

Generated by AI

Topics

Of the messages about AKTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	71.43%	58.63%
Technical Analysis	—	—	28.57%	23.45%
Analysts	—	—	0%	9.75%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	8.17%

Announcements· May 28

Akari Therapeutics' AKTX-101 demonstrated synergy with adagrasib in preclinical KRAS-driven pancreatic cancer models, highlighting the potential of the company's ADC platform.
The company's novel ADC platform uses RNA splicing modulator payloads, offering a differentiated angle in oncology.
CEO Abizer Gaslightwala discussed the breakthrough potential of AKTX-101 and the novel ADC platform in a virtual investor segment following ASCO abstract acceptance.

Technical Analysis· May 22

$AKTX is gearing up for another leg with potential to move to $15.73.
A bullish momentum is expected in the short term, with possible targets at $10+ for dip buys around $8-$9 and a push toward $20+ for breakout entries above $16.
The stock has shown strong momentum, with a 49.85% advance today on volume 44.6 times above average, and the RSI at 52.3 indicating a move with momentum without reaching overbought levels.

Generated by AI

Community

Of the messages about AKTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	85.71%	13.67%
Newcomers	—	—	14.29%	86.33%

Regulars· May 22

$AKTX, Akari Therapeutics, is a biotech developing antibody drug conjugates with a novel RNA splicing modulator payload for oncology, and its stock is up 90% premarket after announcing a $5.5M private placement financing round.
The company has released preclinical data for its lead ADC, AKTX-101, which showed potent single-agent activity and strong synergy with adagrasib in KRAS-mutant tumors, and has been highlighted as a breakthrough at the ASCO 2026 Annual Meeting.
$AKTX is forming a pennant and needs to break the VWAP at 10.43 to continue its upward momentum, with regulars closely watching its price action and technical analysis.

Newcomers· May 29

Akari Therapeutics, Plc ($AKTX) has gained over 250% in a single session, indicating the market's potential to reward innovation before revenue is realized.
The global copper supply is fragile due to structural mining issues, as evidenced by Chile's output decline, which may lead to supply constraints and higher prices.
$AKTX's setup has multiple catalysts, including copper macro trends, exploration at Wilmac, the MetalCore AI angle, and patent applications, making it a speculative yet potentially attractive opportunity.

Generated by AI

Akari Therapeutics

Social

Jul 7

Bullish· May 29

Bearish· May 28

Announcements· May 28

Technical Analysis· May 22

Regulars· May 22

Newcomers· May 29

Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums

Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Moderna (MRNA) and Akari Therapeutics (AKTX)

Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy

Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy

Akari Therapeutics targets mid-2027 phase 1 trial for AKTX-101

Also Discussed

Akari Therapeutics Plc ADR

Company Information

Location

Social

Jul 7

Bullish· May 29

Bearish· May 28

Announcements· May 28

Technical Analysis· May 22

Regulars· May 22

Newcomers· May 29

Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums

Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Moderna (MRNA) and Akari Therapeutics (AKTX)

Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy

Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy

Akari Therapeutics targets mid-2027 phase 1 trial for AKTX-101

Also Discussed